Immunogen traded at $4.61 this Friday July 1st, increasing $0.11 or 2.44 percent since the previous trading session. Looking back, over the last four weeks, Immunogen gained 29.13 percent. Over the last 12 months, its price fell by 28.30 percent. Looking ahead, we forecast Immunogen to be priced at 4.49 by the end of this quarter and at 4.13 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Astellas Pharma 2,123.50 28.00 1.34% 11.50%
AbbVie 153.80 0.64 0.42% 33.54%
Agios Pharmaceuticals 23.36 1.19 5.37% -58.08%
Amgen 245.55 2.25 0.92% -1.27%
AstraZeneca 10,808.00 54.00 0.50% 24.54%
Bluebird Bio 4.28 0.14 3.38% -86.36%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Emergent BioSolutions 31.83 0.79 2.55% -50.08%
Exelixis 21.57 0.75 3.60% 18.13%
Halozyme Therapeutics 44.48 0.48 1.09% -4.18%
Heron Therapeutics 2.72 -0.07 -2.51% -81.71%
Immunogen 4.61 0.11 2.44% -28.30%
Karyopharm Therapeutics 4.73 0.22 4.88% -55.00%
Eli Lilly 324.71 0.48 0.15% 38.79%
MacroGenics 3.05 0.10 3.39% -89.37%
Nektar Therapeutics 3.75 -0.05 -1.32% -78.08%
Novartis 84.36 -0.17 -0.20% -8.28%
Pfizer 52.31 -0.12 -0.23% 31.66%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Roche Holding 322.10 1.70 0.53% -8.06%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Sanofi 51.01 0.98 1.96% -2.60%
Intrexon 1.41 0.07 5.22% -78.04%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Immunogen
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine (IMGN853), IMGN632, MGC936 and IMGN151. Its Mirvetuximab soravtansine is a first-in-class ADC comprising a folate receptor alpha (FRa)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. IMGN632 is an ADC comprised of a high-affinity antibody designed to target CD123 for patients with hematological malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL).